Comprehensive mutational scanning of EGFR reveals TKI ... - Nature
网页2024年3月28日 · Several EGFR extracellular domain variants are dacomitinib-sensitive in vitro and we observed clinical response to dacomitinib in patients whose cancers harbor the G598V mutation. Our study ...
Mechanisms and management of 3rd-generation EGFR-TKI resistance in ...
网页2021年9月24日 · Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), and substantially improves their prognosis.
EGFR TKI as first-line treatment for patients with advanced EGFR ...
网页2017年9月9日 · A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR mutations. Besides, combination strategies based on EGFR TKIs in the first line treatment have also been proved to delay the occurrence of resistance.
Overcoming therapy resistance in EGFR -mutant lung cancer - Nature
网页2021年4月15日 · Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating...
Resistance is futile with fourth-generation EGFR inhibitors
网页2022年4月14日 · Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have revolutionized the treatment of EGFR-mutant non-small cell lung cancer; however, secondary resistance limits...
EGFR-mutated NSCLC: A roadmap to treatment sequences
网页2024年9月13日 · Abstract. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for the management of EGFR-mutated non-small cell lung cancer. Recent results from the HARMONi-A trial lead to considering ivonescimab-a first-in-class, bispecific antibody targeting PD-1 and VEGF-plus chemotherapy as a …
Overall Survival with Osimertinib in Untreated, EGFR-Mutated …
网页2019年11月21日 · Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M...
Osimertinib with or without Chemotherapy in EGFR-Mutated …
网页2023年11月8日 · Osimertinib is a third-generation epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M resistance mutations. Evidence...
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in
网页2024年9月17日 · Tyrosine kinase inhibitors (TKIs) have emerged as a leading targeted cancer therapy, reducing the side effects often seen with non-targeted treatments, especially the damage to healthy cells. To tackle resistance, typically caused by epidermal growth factor receptor (EGFR) mutations, four generations of TKIs have been developed. Each …
PrPC controls epithelial-to-mesenchymal transition in EGFR …
网页Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR.Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is …
- 某些结果已被删除
跳至内容